Kornimate/medical-research-clean huggingface dataset:
wild 5 wellness, a 30-day intervention

Conditions: Anxiety; Depression; Cognitive Functioning; Wellness

Summary: the purpose of this study is to explore the efficacy and feasibility of an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition in first year beloit college students self-selected into a wellness focused first year initiative. this program is called "wild 5 wellness: a 30-day intervention".


Eligibility criteria:
inclusion criteria: * students 18 years of age or older or 17 years of age with legal guardian written permission. * students enrolled in first year initiative courses titled "balance" or "constructing health" exclusion criteria: * individuals who are pregnant or plan to get pregnant during the next 30 days. * students who are not enrolled in the first year initiative courses titled "balance" or "constructing health"
a mindfulness-based cognitive therapy for suicidal patients

Conditions: Suicidal Ideation; Suicide Attempt

Summary: the main goal of this study is to evaluate the effectiveness ofmindfulness-based cognitive therapy aimed at reducing suicidality in adults. this will test the effectiveness by studying the effect on suicidal ideation and related outcomes, compared to treatment as usual. the study is a multicentre randomized controlled trial conducted in out-patient flemish mental healthcare facilities.


Eligibility criteria:
inclusion criteria: * speak dutch * be at least 18 years old * have access to internet * be suitable for group therapy * have mild to severe suicidal thoughts (bss score of minimum 1) exclusion criteria: * conditions expected to severely hinder group participation, comprehension of the training content or adherence
efficacy of preoperative pectoral nerve block for intraoperative opioid sparing effect and postoperative analgesia

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether pectoral nerves blocks（pecs） would reduces the opioid consumption during the surgery and postoperative pain after breast cancer surgery.

forty adult female participants scheduled for elective breast cancer surgery under general anesthesia are randomly allocated to receive either general anesthesia plus pecs block(pecs group, n=20) or general anesthesia alone (control group, n=20). after arrived in the operating room，all patients undergo operation under total intravenous anesthesia (tiva) with or without pectoral nerves blocks(pecs) . after anesthesia induction，the participants in the pecs group receive an ultrasound-guided pecs block before the start of the operation. pecs block technology：after cleaning the infraclavicular and axillary regions , the linear probe is placed below the lateral third of the clavicle. after recognition of the appropriate anatomical structures, then the block is performed . the needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 ml of 0.5% ropivacaine deposited. in a similar manner, 20 ml is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle . during operation the remifentanil administration in each group is guided using the surgical pleth index( spi). the spi target range was 20 to 50 anesthetic depth is maintained and continuously adjusted with propofol to achieve bispectral index (bis) between 40 and 60. primary outcome intraoperative remifentanil consumption secondaty outcome postoperative pain score and rescue analgesic requirement

Eligibility criteria:
inclusion criteria: american society of anesthesiologists( asa) i or ii scheduled for breast cancer surgery exclusion criteria: sensitivity to local anesthetic, bleeding disorders , receiving anticoagulant, body mass index (bmi) \> 35/kg/m2 , spine or chest wall deformity , pregnancy
the effect of self-management program based on the individual and family self-management theory on cancer patients

Conditions: Oncology; Fatigue; Patient

Summary: the purpose of this study is to evaluate the effect of self-management program based on the individual and family self-management theory on fatigue, daily living activities and well-being of cancer patients.


Eligibility criteria:
inclusion criteria: * inpatients for symptom management or supportive care in oncology wards * patients who were at first two days of hospitalization * patients who had score of 3≤ or ≤7 in fatigue visual analogue scale (vas) * patients who had score of ≤5 in pain analog visual scale (vas) * patients who had score of ≤5 the modified borg scale * patients who had score of 0, 1, 2 or 3 in ecog performance scale * patients who had metastases * patients who were over 18 years of age * patients who had orientation of person, place and time * patients who had no communication barriers * patients who agreed to participate in the study exclusion criteria: * patients who had hospitalized for the purpose of receiving chemotherapy * patients whose hb value was ≤8 g / dl * patients whose body temperature ≥ 38.5 ° c within the last 24 hours * patients who had diarrhea in the last 24 hours (frequency of defecation ≥ 3 / day) * patients who had a score of ≤ 16 kg / m2 in body mass index (bmi) * patients who had advanced heart failure * patients who had untreated hypothyroidism * patients who diagnosed with major depression and / or treated for depression * patients who had no family member involved in their care

Keywords: nursing cancer patients self-management fatigue activities of daily living well-being randomized controlled trial
influence of overground walking on biomarkers, cognitive function, and quality of life in elderly with mild cognitive impairment

Conditions: Cognitive Impairment; Aging

Summary: the purpose of this research is to investigate the impact of overground walking as a part of a rehabilitation program on the increase in brain-derived neurotrophic factor (bdnf) levels, decrease in il-6 levels, decrease in hs-crp levels, improvement in cognitive function, and enhancement of quality of life (qol) in older people with mild cognitive impairment. these findings are anticipated to contribute to the efforts to elevate bdnf levels, cognitive function, and qol while reducing il-6 and hscrp levels in the elderly with mild cognitive impairment.

this research employs a quasi-experimental research design using a pretest-posttest design approach. the pretest-posttest method is executed by assessing before and after the intervention within the same group. all research subjects receive the same treatment, which involves participating in an overground walking program on a flat surface. the selected research subjects are provided with an explanation of the research's objectives and benefits and the exercise and examination procedures, then sign the informed consent. research subjects are instructed to walk on a flat surface for a distance of 15 meters, with a duration of 20 minutes, increasing by 5 minutes each week until the target heart rate is achieved during the exercise. after an 8-week post-intervention period, research subjects will undergo a follow-up examination.

Eligibility criteria:
inclusion criteria: * mild cognitive impairment (moca ina score 19-25 out of 30 * barthel index score 20 * geriatric depression scale score ≤ 5 * timed up and go test \< 15 seconds) * capable of comprehending verbal and written instructions * capable of walking unassisted exclusion criteria: * the presence of hearing impairment that could hinder the subject from receiving verbal instructions, * the presence of uncorrected visual impairment * having musculoskeletal disorders * receiving other rehabilitation programs, * presence of diseases causing cognitive impairment * severe joint diseases such as osteoarthritis and rheumatoid arthritis that may worsen during exercise or could pose difficulties in carrying out the exercise program, * severe cardiovascular diseases as diagnosed by a cardiologist

Keywords: exercise rehabilitation
non-invasive assessment of immediate postoperative analgesia using analgesia/nociception index (ani)

Conditions: Postoperative Pain

Summary: the aim of this study is to evaluate the clinical performance on analgesia/nociception index (ani) in the assessment of immediate postoperative analgesia in pacu in adult patients undergoing general anesthesia.

evaluation of the relationship between ani and numerical rating pain scale (nrs) by linear regression. assessment of the performance of ani to detect nrs\>3 and nrs\>=7 by building roc curves.

Eligibility criteria:
inclusion criteria: * adult * surgical or endoscopic procedures performed on general anesthesia exclusion criteria: * age \ 75 yrs * arrythmia * administration of anticholinergic drugs or neuromuscular blockade reversal in the 20 previous minutes * psychiatric diseases * autonomic nervous system (ans) disorders * inability to understand the verbal rating pain scale.

Keywords: analgesia/nociception index
effect tdcs of motor cortex on chemotherapy induced peripheral neuropathy

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: chemotherapy induced peripheral neuropathy (cipn) occurs in conjunction with the use of anticancer medication such as vinca alkaloids (including vincristine), taxanes (including paclitaxel), and platinum preparations (including cisplatin and oxaliplatin)

chemotherapy induced peripheral neuropathy (cipn) occurs in conjunction with the use of anticancer medication such as vinca alkaloids (including vincristine), taxanes (including paclitaxel), and platinum preparations (including cisplatin and oxaliplatin) . cipn is one of several long term side effects of anticancer medications that can appear during and after treatment. cipn symptoms include pain, dysesthesia, motor and sensory disorders. cipn can also be insufficiently responsive to pharmaceutical therapy similar to other types of refractory neuropathic pain this study is designed to evaluate the effect of two concentric electrode transcranial direct current stimulation (ce-tdcs) over the primary motor cortex (m) in management of chemotherapy induced peripheral neuropathy.

Eligibility criteria:
inclusion criteria: * any stage of cancer, with a confirmed treatment plan consisting of taxane-based or oxaliplatin-based chemotherapy, neuropathic pain and/or peripheral sensory neuropathy with vas score ≥ 3 that are resistant to medical treatment exclusion criteria: * patients with intracranial metallic devices or with pacemakers or any other device. - -w those with extensive myocardial ischemia, * higher brain dysfunction, * migraine headache, * brain cancer or metastasis and * those known to have epilepsy

Keywords: brain stimulation chemotherapy induced peripheral neuropathy
management of cancer therapy related vulvovaginal atrophy

Conditions: Genitourinary Syndrome of Menopause

Summary: the goal of this clinical trial is to: 1. evaluate the efficacy of prp injection and prp injection mixed with non-cross-linked hyaluronic acid compared to the control group receiving standard therapy with topical non-cross-linked hyaluronic acid gel in the treatment of cancer therapy-induced or worsened vulvovaginal atrophy. 2. to evaluate the impact of vulvovaginal atrophy treatment on the sexual satisfaction of both partners. patients will be divided randomly into 3 groups: group 1: 15 female patients will receive vaginal prp injections. group 2: 15 female patients will receive vaginal prp injections combined with non-cross-linked hyaluronic acid. group 3: 15 female patients will receive topical non-cross-linked hyaluronic acid gel as a control group.

1. the first group will receive two treatment of sub-mucosal prp injection at the outer 3 cm of the vagina with one month interval in between. (17) 2. the second group will receive two treatment of prp injection mixed with non-cross linked hyaluronic acid at the outer 3 cm of the vagina with one month interval in between. 9. 3-the third group will receive one applicator (5gm) three times per week of topical hyaluronic acid gel for vaginal application which will be prepared in the faculty of pharmacy for 2 months. clinical assessment patients will be assessed for symptoms and signs of vulvovaginal atrophy (vva) at baseline, one month, two months, and, three months after the end of treatment. 1. vulvovaginal atrophy (vva) symptoms (dryness, dyspareunia) will be assessed on a subjective 10-point scale. also, patient satisfaction with each type of treatment will be assessed with a questionnaire at the end of treatment and they will be asked if they wish to repeat the treatment to maintain effectiveness over time (yes or no). 2. for assessment of vva signs on physical examination, vaginal health index including assessment of ph, overall elasticity, epithelial mucosa, fluid secretion type, and consistency and moisture will be used as an objective method of evaluation of therapy. 3. assessment of sexual satisfaction of both male and female partners: sexual satisfaction was measured using the arabic version of the index of sexual satisfaction (iss) and female sexual function index (fsfi) questionnaire.

Eligibility criteria:
inclusion criteria: * patients have symptoms of vva (vaginal dryness, burning, itching or dyspareunia) * patients with vaginal health index \< 15. * all patients have already finished cancer therapy or are on anti-estrogen treatment. * married sexually active * patients who are not receiving any vva treatment for at least 30 days before starting therapy. exclusion criteria: * active or recent history of vulvovaginal inflammation or infection * history of vulvar or vaginal cancer. * suspicious lesion in the vulvovaginal area on the gynecological examination
basket trial in solid tumors harboring a fusion of fgfr1, fgfr2 or fgfr3- (fuze clinical trial)

Conditions: Solid Tumor

Summary: the primary objective of this study is to assess the efficacy of debio 1347 in terms of objective response rate (orr) in participants with solid tumors harboring fibroblast growth factor receptor (fgfr)1-3 gene fusion/rearrangement.


Eligibility criteria:
inclusion criteria: * cytologically or histologically confirmed advanced solid tumor * radiographic progression on prior systemic therapy; prior localized therapy (i.e., radiation, ablation, embolization) is allowed provided radiographic progression out-of-field or in the treatment, field is shown * locally-advanced (unresectable) or metastatic disease harboring an fgfr1-3 gene fusion/rearrangement potentially leading to a functional fgfr aberrant protein, identified through local and/or central molecular assay exclusion criteria: * history of hypersensitivity to any of the excipients in the debio 1347 formulation * history and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes, lung nodules and asymptomatic vascular or cartilage/tendon calcifications * administration of any investigational agent within 2 weeks prior to initial dosing with debio 1347 (3 weeks for immune checkpoint inhibitors)
preoperative gabapentin for post-tonsillectomy pain in children

Conditions: Post Operative Pain Management in Children With Tonsillectomy/Adenoidectomy

Summary: the typical post-operative course for children following surgical removal of their tonsils and adenoids can be challenging, especially for pain control. first line medications for pain include intravenous and enteral narcotics, acetaminophen and nonsteroidal anti-inflammatory drugs (nsaids) or n-methyl-d-aspartate (nmda) antagonists but their effects appear to be short-lived. gabapentin has been shown in adult studies to tone down the body's response to pain and decreases opioid use post-operatively. the purpose of this study is to see if a single preoperative dose will reduce post-operative pain scores and the amount of analgesic used.

this is a randomized, double blind, placebo-controlled trial to study the effect of a preoperative oral dose of gabapentin on postoperative analgesic requirements and subjective pain levels in children undergoing tonsillectomy with adenoidectomy. investigators will also look for a limited set of genotypic variations to explain any difference between individuals or groups in their response to the medication. additionally, investigators will document potential adverse effects including excessive sedation, respiratory issues, surgical bleeding and emergence agitation/delirium. investigators hypothesize that gabapentin will reduce opioid analgesic requirements and pain scores up to 36 hours post adenotonsillectomy without increased adverse effects such as emergence delirium, respiratory complications or bleeding. the clinical effect may depend on the individual's pharmacogenetic profile to look for a specific set of genetic polymorphisms that relate to the metabolism and effect of the study drug, gabapentin, and opioid analgesic pain medications.

Eligibility criteria:
inclusion criteria: * scheduled for outpatient tonsillectomy and adenoidectomy * \< 60 kg, between 5th and 95th percentile for weight * ability to self-report pain * complete pain diary with assistance from parent or guardian exclusion criteria: * require pre-anesthesia medication for anxiety * require interpreter for verbal or written communication * obstructive sleep apnea significant enough to not qualify for outpatient surgery per surgeon * ongoing oxygen dependence, pulmonary hypertension * elevated risk of regurgitation * history of seizures * currently taking psychoactive medications or having a psychiatric condition requiring medications * chronic pain disorders requiring medications * renal disease * developmental or cognitive disabilities * history of adverse reactions to components of liquid gabapentin or placebo

Keywords: pediatric pain post operative pain opioids emergence agitation preoperative anxiety pharmacogenomics
a study of two doses of dulaglutide (ly2189265) in japanese patients with type 2 diabetes

Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases; Hypoglycemic Agents; Type 2 Diabetes Mellitus (T2DM)

Summary: the purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in japanese participants with type 2 diabetes. the study duration is approximately 58 weeks.


Eligibility criteria:
inclusion criteria: * participants with type 2 diabetes (t2d) ≥ 6 months according to the world health organization (who) classification. * treated with stable doses of a single oam for at least 8 weeks prior to screening; the dose must be more than or equal to minimum maintenance dose. * have the following hba1c result at screening. * participants taking dpp-4i: ≥7.5% and ≤9.5%, * participants taking another oam: ≥8.0% and ≤10.0% * stable body weight for at least 8 weeks prior to screening or not changed by more than 5 % in the past 8 weeks * have a body mass index (bmi) ≥18.5 kilogram/square meter (kg/m²) and \<35 kg/m² at day 1. exclusion criteria: * have type 1 diabetes (t1d) * have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma * have had any myocardial infarction (mi), heart failure or cerebrovascular accident (stroke) * have a known clinically significant gastric empty abnormality * have acute or chronic hepatitis * have had chronic or acute pancreatitis * have any self or family history of type 2a or type 2b multiple endocrine neoplasia in the absence of known c-cell hyperplasia * have any self or family history of medullary c-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of multiple endocrine neoplasia (men) 2a or 2b syndrome) * have evidence of significant, active autoimmune abnormality * have evidence of significant, uncontrolled endocrine abnormality * have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years * have any hematologic condition that may interfere with hba1c measurement
evaluation of two toric soft contact lenses after two weeks of wear

Conditions: Astigmatism

Summary: the purpose of this study is to determine the relative performance of a new toric soft contact lens against a toric contact lens currently available in market, specifically with regards to the comfort and vision after two weeks of use.

dispensing, single-masked (subject-masked), randomized, 2-visit controlled study of two-weeks duration.

Eligibility criteria:
inclusion criteria: prior to being considered eligible to participate in this study, subjects must 1. be at least 18 and less than or equal to 39 years of age and have a need for vision correction in both eyes (monovision or uniocular fitting is not allowed). 2. be of asian descent (japanese, chinese, korean, polynesian or other asian ancestry) and have asian eye anatomy. 3. have successfully worn toric or spherical soft (hydrogel or silicone hydrogel) contact lenses for at least 4-weeks prior to enrollment in the study. 4. be able and willing to adhere to the instructions set forth in the protocol. 5. agree to wear their contact lenses in both eyes on a daily wear schedule for at least 8 hours per day every day during the study. 6. have a distance spherical component between -1.00 d and -5.50 d with cylinder in the range of 0.75 d to 2.25 d and cylinder axis within 10 ° of the vertical and within 20 ° of the horizontal in both eyes 7. have a best corrected manifest refraction visual acuity of at least 20/25 or better in each eye. 8. be in good general health, based on his/her knowledge. 9. read, be given an explanation of, indicate understanding of, and sign the statement of informed consent. exclusion criteria: 1. the subject is a rigid gas permeable (rgp) or daily disposable soft lens wearer. 2. the presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures. 3. the presence of ocular or systemic disease or need for medication which might interfere with contact lens wear or which would cause the lenses to be removed more than twice a day. (i.e., sjögren's syndrome, type ii diabetes, etc). 4. slit lamp findings that would contraindicate contact lens wear such as: * pathological dry eye or associated findings * pterygium or corneal scars within the visual axis * neovascularization \>1mm in from the limbus * history of giant papillary conjunctivitis (gpc) worse than grade 2 * anterior uveitis or iritis (past or present) * seborrhoeic eczema, seborrhoeic conjunctivitis 5. a history of recurrent erosions, corneal infiltrates, corneal ulcer or fungal infections. 6. a known history of corneal hypoesthesia (reduced corneal sensitivity.) 7. aphakia, keratoconus or a highly irregular cornea. 8. current pregnancy or lactation (to the best of the subject's knowledge). 9. active participation in another clinical study at any time during this study.

Keywords: astigmatism vision comfort satisfaction contact lenses